Genentech/OSI's Tarceva Will Be Detailed Alongside Herceptin
This article was originally published in The Pink Sheet Daily
Executive Summary
Tarceva approval comes just three-and-a-half months after application is completed and more than two months ahead of review deadline. Genentech and OSI will begin detailing the non-small cell lung cancer product immediately.
You may also be interested in...
Tarceva Survival Advantage In Pancreatic Cancer Not "Clinically Meaningful," FDA Says
The agency's briefing documents for Tarceva's Oncologic Drugs Advisory Committee review raise concerns about rates of serious adverse events and treatment-related fatalities.
Tarceva Survival Advantage In Pancreatic Cancer Not "Clinically Meaningful," FDA Says
The agency's briefing documents for Tarceva's Oncologic Drugs Advisory Committee review raise concerns about rates of serious adverse events and treatment-related fatalities.
Tarceva New Rx Share Doubles Since Release Of Failed Iressa Survival Study
New prescription share for Genentech/OSI’s oncologic jumps from about 40% to above 80% following news that AstraZeneca’s Iressa failed to demonstrate a survival benefit. Tarceva sales growth will depend on the ability to differentiate the drug’s profile from that of Iressa, OSI exec says.